, /PRNewswire/ -- , a start-up bringing the first multiplex, high-throughput tools to epigenomic research, today unveiled its EpiFinderTM Platform with a patented high-throughput, multiplexing, quantitative ChIP-seq (hmqChIP-seq) technology and launched EpiFinder Genome for comprehensive genome-wide profiling. EpiFinder Genome, the company's flagship product and the first commercial kit of its kind, simultaneously targets up to eight markers in up to 24 samples or independent replicates, generating quantitative data for in-depth insights into biomedical research, drug discovery and development, diagnostics, and precision medicine. "We are incredibly excited today to share with the global scientific community our EpiFinder platform, a groundbreaking technology for epigenomic research, and to commercially launch EpiFinder Genome," said Epigenica CEO and co-founder , PhD.
"The development of these technologies has been a true labor of love for our team and marks an important milestone for Epigenica as we advance our mission to bring unprecedented scale, speed, and affordability to the rapidly growing field of epigenetics." External factors, such as aging, the environment, and lifestyle, can play an essential role in how genes function by making long-lived chemical modifications, or epigenetic marks, to our DNA or histone proteins that wrap the DNA. While epigenetics holds great promise for basic science, drug discovery and development, diagnostics, and precision medicine, curren.